Clinical Trials on Moderate to Severe Glabellar Lines in Switzerland
Total 10 results
-
Merck KGaA, Darmstadt, GermanyCompletedModerate to Severe PsoriasisSwitzerland
-
Merck KGaA, Darmstadt, GermanyCompletedModerate to Severe PsoriasisSwitzerland
-
NestléCompletedMild to Moderate Levels of StressSwitzerland
-
Raphaelle Jaquet-PilloudSwiss Foundation for the Health of Children and AdolescentsCompletedModerate to Severe BronchiolitisSwitzerland
-
AbbVie (prior sponsor, Abbott)CompletedModerate to Severe Plaque PsoriasisUnited States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
-
Novartis PharmaceuticalsCompletedModerate to Severe Plaque-type PsoriasisUnited States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
-
Novartis PharmaceuticalsCompletedModerate to Severe Chronic Plaque-Type PsoriasisUnited States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
-
Creabilis SATerminated
-
Edwards LifesciencesICON plcTerminatedSevere Degenerative Mitral Regurgitation Due to Mid-segment Posterior Leaflet ProlapseGermany, Spain, Switzerland